Brief: Larimar Therapeutics Announces FDA Clearance To Initiate The 25 Mg Cohort Of A Phase 2 Dose Exploration Trial Of Cti-1601 In Friedreich’S Ataxia Patients

Larimar Therapeutics

14/09/2022 12:08

Sept 14 (Reuters) - Larimar Therapeutics Inc  LRMR.O :
    * LARIMAR THERAPEUTICS ANNOUNCES FDA CLEARANCE TO INITIATE
THE 25
MG COHORT OF A PHASE 2 DOSE EXPLORATION TRIAL OF CTI-1601 IN
FRIEDREICH’S ATAXIA PATIENTS
    * LARIMAR THERAPEUTICS INC - INITIATION OF PHASE 2 TRIAL IS
EXPECTED IN Q4 2022, WITH TOP-LINE DATA EXPECTED IN 2H 2023

Source text for Eikon:  ID:nGNX38Tdx 
Further company coverage:  LRMR.O 

 ((Reuters.Briefs@thomsonreuters.com;))